4.6 Review

Cellular players in angiogenesis during the course of systemic sclerosis

Journal

AUTOIMMUNITY REVIEWS
Volume 10, Issue 10, Pages 641-646

Publisher

ELSEVIER
DOI: 10.1016/j.autrev.2011.04.016

Keywords

Systemic sclerosis; Endothelial progenitor cells; Ischemia; Vasculogenesis; Mesenchymal stem cells

Categories

Funding

  1. PRIN 2008 [200884K784]
  2. FIRA ONLUS 2009

Ask authors/readers for more resources

Vascular endothelial injury in Systemic Sclerosis (SSc) leads to pathological changes in the blood vessels that adversely impact the physiology of many organs, resulting in chronic tissue ischemia. The response to hypoxia induces complex cellular and molecular mechanisms in the attempt to recover endothelial cell function and tissue perfusion. The progressive losses of capillaries on one hand, and the vascular remodeling of arteriolar vessels on the other, result in insufficient blood flow, causing severe and chronic hypoxia. Hypoxia is a major stimulus of angiogenesis, leading to the expression of pro-angiogenic molecules, mainly of Vascular Endothelial Growth Factor (VEGF), which triggers the angiogenic process. Nevertheless, in SSc patients there is no evidence of adaptive angiogenesis. Failure of the angiogenic process in SSc largely depends on alteration in the balance between pro- and anti-angiogenic factors, as well as on functional alterations of the cellular players involved in the angiogenic and vasculogenic program. A decreased urokinase plasminogen activator (uPA) dependent invasion, proliferation, and capillary morphogenesis, was showed in SSc endothelial cells (EC). Although hematopoietic endothelial progenitor cells (EPC) count in the peripheral blood of SSc patients is still a matter of controversy, alterations in mobilization process, an excessive immune-mediated EPC destruction in the peripheral circulation or in the bone marrow, a progressive depletion of EPCs following homing to ischemic tissues under persistent peripheral vascular injury, an intrinsic functional impairment could lead to poor vasculogenesis. Human mesenchymal stem cells represent an alternative source of endothelial progenitor cells and it has been observed that their angiogenic potential is reduced in SSc. Targeting autologous stem and progenitor cells could be an ideal tool to counteract and repair dysfunctional angiogenesis. (C) 2011 Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Rheumatology

Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon et al

Paola Di Benedetto, Paola Cipriani, Piero Ruscitti, Vasiliki Liakouli, Roberto Giacomelli

ANNALS OF THE RHEUMATIC DISEASES (2020)

Article Rheumatology

Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre real-life cohort

Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli, Daniela Iacono, Ilenia Pantano, Francesco Caso, Federico Perosa, Fabiola Atzeni, Francesco Paolo Cantatore, Raffaele Scarpa, Francesco Ciccia, Roberto Giacomelli

RHEUMATOLOGY INTERNATIONAL (2020)

Article Medicine, Research & Experimental

Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study

M. Prete, E. Favoino, R. Giacomelli, A. Afeltra, F. P. Cantatore, C. Bruno, A. Corrado, L. Emmi, G. Emmi, R. D. Grembiale, L. Navarini, A. Marcoccia, V Liakouli, A. Riccardi, G. Valentini, F. Perosa

CLINICAL AND EXPERIMENTAL MEDICINE (2020)

Review Immunology

Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm

Piero Ruscitti, Onorina Berardicurti, Paola Di Benedetto, Paola Cipriani, Annamaria Iagnocco, Yehuda Shoenfeld, Roberto Giacomelli

FRONTIERS IN IMMUNOLOGY (2020)

Article Rheumatology

Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences

Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, Alessandro Conforti, Francesco Carubbi, Ilenia Di Cola, Paola Di Benedetto, Paola Cipriani, Davide Grassi, Carlo Masciocchi, Annamaria Lagnocco, Antonio Barile, Roberto Giacomelli

ANNALS OF THE RHEUMATIC DISEASES (2020)

Review Immunology

Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis

Vasiliki Liakouli, Jacopo Ciaffi, Francesco Ursini, Piero Ruscitti, Riccardo Meliconi, Francesco Ciccia, Paola Cipriani, Roberto Giacomelli

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)

Review Immunology

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus

Roberto Giacomelli, Antonella Afeltra, Elena Bartoloni, Onorina Berardicurti, Michele Bombardieri, Alessandra Bortoluzzi, Francesco Carubbi, Francesco Caso, Ricard Cervera, Francesco Ciccia, Paola Cipriani, Emmanuel Coloma-Bazan, Fabrizio Conti, Luisa Costa, Salvatore D'Angelo, Oliver Distler, Eugen Feist, Nathan Foulquier, Marco Gabini, Vanessa Gerber, Roberto Gerli, Rosa Daniela Grembiale, Giuliana Guggino, Ariela Hoxha, Annamaria Iagnocco, Suzana Jordan, Bashar Kahaleh, Kim Lauper, Vasiliki Liakouli, Ennio Lubrano, Domenico Margiotta, Saverio Naty, Luca Navarini, Federico Perosa, Carlo Perricone, Roberto Perricone, Marcella Prete, Jacques-Olivier Pers, Costantino Pitzalis, Roberta Priori, Felice Rivellese, Amelia Ruffatti, Piero Ruscitti, Raffaele Scarpa, Yehuda Shoenfeld, Giovanni Triolo, Athanasios Tzioufas

Summary: Autoimmune diseases share common clinical features but have different pathogenic mechanisms and targeted organs. Applying precision medicine principles may improve treatment success by tailoring therapy to individual characteristics and reducing adverse events.

AUTOIMMUNITY REVIEWS (2021)

Article Immunology

Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity

Elvira Favoino, Ettore Grapsi, Giovanna Barbuti, Vasiliki Liakouli, Piero Ruscitti, Caterina Foti, Roberto Giacomelli, Federico Perosa

Summary: This study evaluated whether anti-centromeric protein A (CENP-A) antibodies cross-react with mitochondrial antigens. The results showed that antibodies with a specific mitochondrial antigen (PDC-E2) cross-reacted with anti-centromere antibodies (Ap1-17). This finding is important for investigating the pathogenic significance of these antibodies.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2023)

Article Rheumatology

Novel biomarker for pulmonary vascular disease in systemic sclerosis patients

E. Favoino, G. Catacchio, A. Mininni, P. Ruscitti, V. Riccieri, V. Liakouli, A. Corrado, L. Navarini, F. Ciccia, P. Cipriani, F. P. Cantatore, G. Valesini, R. Giacomelli, F. Perosa

Summary: Anti-p4.2 antibodies can identify a subset of systemic sclerosis (SSc) patients at a high risk of developing pulmonary vascular disease (PVD), even in the absence of pulmonary fibrosis (PF).

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2022)

Article Rheumatology

Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study

P. Ruscitti, P. Cipriani, V Liakouli, D. Iacono, I Pantano, D. P. E. Margiotta, L. Navarini, G. M. D. Castaniti, N. Maruotti, G. Di Scala, F. Caso, S. Bongiovanni, R. D. Grembiale, F. Atzeni, R. Scarpa, F. Perosa, G. Emmi, F. P. Cantatore, G. Guggino, A. Afeltra, F. Ciccia, R. Giacomelli

Summary: The study observed an increased incidence of high blood pressure, type 2 diabetes, and metabolic syndrome in participants with rheumatoid arthritis. Maintaining remission and therapy with hydroxychloroquine were reported to reduce the risk of developing these cardiovascular risk factors.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2021)

Meeting Abstract Rheumatology

THE ANTI-ANGIOGENIC ROLE OF TOFACITINIB DURING EXPERIMENTAL MODEL OF ARTHRITIS

P. Cipriani, P. Di Benedetto, P. Ruscitti, O. Berardicurti, V. Liakouli, F. Carubbi, N. Panzera, N. Grazia, M. Di Vito Nolfi, B. Di Francesco, A. Maurizi, N. Rucci, A. Teti, F. Zazzeroni, E. Alesse, R. Giacomelli

ANNALS OF THE RHEUMATIC DISEASES (2020)

Article Rheumatology

Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients

Piero Ruscitti, Onorina Berardicurti, Daniela Iacono, Ilenia Pantano, Vasiliki Liakouli, Francesco Caso, Giacomo Emmi, Rosa Daniela Grembiale, Francesco Paolo Cantatore, Fabiola Atzeni, Federico Perosa, Raffaele Scarpa, Giuliana Guggino, Francesco Ciccia, Antonio Barile, Paola Cipriani, Roberto Giacomelli

ARTHRITIS RESEARCH & THERAPY (2020)

Article Rheumatology

Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension

Paola Di Benedetto, Giuliana Guggino, Giovanna Manzi, Piero Ruscitti, Onorina Berardicurti, Noemi Panzera, Nicolo Grazia, Roberto Badagliacca, Valeria Riccieri, Carmine Dario Vizza, Ganna Radchenko, Vasiliki Liakouli, Francesco Ciccia, Paola Cipriani, Roberto Giacomelli

ARTHRITIS RESEARCH & THERAPY (2020)

No Data Available